期刊文献+

99Tcm-MAG3-isoDGR-2C分子探针的制备与体内分布的实验研究

Labeling MAG3-isoDGR-2C with 99Tcm and its biodistribution in mice
原文传递
导出
摘要 目的 摸索99Tcm-MAG3-isoDGR-2C分子探针的标记条件并研究其在正常昆明小鼠体内的生物学分布.方法 利用葡庚糖酸盐(GH)转换络合法进行标记,即首先用99Tcm标记GH形成99TcmO-GH中间体,再进行99Tcm-MAG3-isoDGR-2C的标记;考察pH值和温度等因素对标记率的影响,采用高效液相色谱法鉴定标记物的放射化学纯度;取30只昆明小鼠随机分成6组,分另于注射99cm-MAG3-isoDGR-2C 15、30、60、120、240和360 min后测定其在小鼠体内的分布情况.结果 pH值为4.6、反应温度为100℃时的标记率最高(94.2%).体内分布研究显示该标记物能够较快地从血液中清除,且心、肺、脾、胃、骨等组织的放射性摄取均很少.结论 99Tcm-MAG3-isoDGR-2C标记率高、血液清除快,具备一定的成为SPECT显像剂的条件. Objective To analyze the feasibility of labeling MAG3-isoDGR-2C with 99Tcm and investigate the biodistribution of the tracer in normal mice.Methods Glucoheptonate was initially labeled with 99Tcm as the intermediate,followed by MAG3-isoDGR-2C.High-performance liquid chromatography was employed to determine the radiochemical purity.The biodistribution of 99Tcm-MAG3-isoDGR-2C was studied at 15,30,60,120,240 and 360 min after caudal vein injection in normal mice.Results MAG3-isoDGR-2C was successfully labeled with 99Fcm,and the radiochemical purity was 94.2%.The biodistribution revealed that the tracer was rapidly cleared out from the blood with mild activity in the heart,lung,spleen,stomach,and bone.Conclusions MAG3-isoDGR-2C was labeled with 99Tcm with high radiochemical purity,and the tracer could be cleared out quickly.Therefore,MAG3-isoDGR-2C is a potential molecular tracer in the study of early cancer diagnosis.
出处 《国际放射医学核医学杂志》 2016年第5期345-349,共5页 International Journal of Radiation Medicine and Nuclear Medicine
基金 河北省自然科学基金(H2014206286)
关键词 分子探针 同位素标记 异天冬氨酸-甘氨酸-精氨酸 体内分布 Molecular probes Isotope labeling IsoAsp-Gly-Arg Biodistribution
  • 相关文献

参考文献3

二级参考文献28

  • 1蔡炯,李方,郑连芳,张迎强,蒲圻,王世真.人膜联蛋白V的重组表达与细胞凋亡显像[J].基础医学与临床,2006,26(8):913-914. 被引量:2
  • 2蔡炯,李方,张迎强,郑连芳,蒲圻.突变型人膜联蛋白V的重组表达[J].中国医学科学院学报,2006,28(4):549-552. 被引量:5
  • 3Kerr JF,Winterford CM,Harmon BV.Apoptosisi:Its significance in cancer and cancer therapy.Cancer,1994,73(8):2013-2026
  • 4Lahorte CM,Vanderheyden JL,Steinmetz N,et al.Apoptosis-detecting radioligands:current state of the art and future perspectives.Eur J Nucl Med Mol Imaging,2004,31:887-919
  • 5Boersma HH,Kietselaer BL,Stolk LM,et al.Past,present,and future of annexin A5:from protein discovery to clinical applications.J Nucl Med,2005,46(12):2035-2050
  • 6Van Heerde WL,de Groot PG.Reutelingsperger CPM.The complexity of the phospholipid binding protein annexin V.Thromb Haemost,1995,73:172-179
  • 7Vermeersch H,Ham H,Rottey S,et al.Intraobserver,interobserver,and day-to-day reproducibility of quantitative 99mTc-HYNIC annexin-V imaging in head and neck carcinoma.Cancer Biother Radiopharm,2004,19(2):205-210
  • 8Kartachova M,Haas RL,Olmos RA,et al.In vivo imaging of apoptosis by ^99mTc-annexin V scintigraphy:visual analysis in relation to treatment response.Radiother Oncol,2004,72(3):333-339
  • 9Tait JF,Brown DS,Gibson DF,et al.Development and characterization of annexin V mutants with endogenous chelation sites for ^99mTc.Bioconjugate Chem,2000,11:918-925
  • 10Mather SJ, Ellison D. Reduction-mediated ^99Tc^m Iabelling monoclonal antibodies. J Nucl Med, 1990, 31 : 692-697.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部